The use of AI in biotechnology is changing faster than the rules governing either technology

The emergence of AI-generated viruses and other advanced biotechnologies is outstripping the regulatory frameworks designed to govern them. While these tools have the potential to revolutionize medicine, agriculture and the environment, they also introduce significant risks that existing regulations struggle to anticipate or contain.

The convergence of AI, precision gene-editing, and synthetic biology creates an intricate web of technologies that defy traditional categorization. Regulators worldwide are grappling with how to balance the promise of these innovations with the need to manage potential dangers. In New Zealand, the Gene Technology Bill is seeking to address this issue by proposing a more flexible regulatory framework, exempting lower-risk gene-editing technologies while retaining oversight for higher-risk activities.

However, this approach requires careful calibration to ensure innovation is not unduly stifled. Similar challenges are faced in Australia and the United States, each with their unique regulatory systems that must adapt to the rapidly evolving landscape of biotechnology. The European Union, traditionally one of the most cautious regulators, has also been adapting its rules to accommodate the lower-risk aspects of CRISPR technology while maintaining oversight for more complex applications.

Ultimately, the goal is to establish a regulatory framework that can flexibly distinguish between different levels of risk, enabling beneficial research to proceed while subjecting high-risk activities to greater scrutiny.